Drug Profile
AG 2195
Alternative Names: AG-2195Latest Information Update: 14 Aug 2007
Price :
$50
*
At a glance
- Originator Corixa Corporation
- Class
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myasthenia gravis
Most Recent Events
- 17 May 2005 No development reported - Preclinical for Myasthenia gravis in Europe (unspecified route)
- 30 May 2003 Beaufour-Ipsen is now called Ipsen
- 22 Jan 2002 Beaufour Ipsen has acquired a licence for worldwide development and marketing of AG 2195 from Corixa Corporation